Compare FNUC & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNUC | CYPH |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | Canada | United States |
| Employees | N/A | 6 |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.6M | 73.4M |
| IPO Year | 2021 | N/A |
| Metric | FNUC | CYPH |
|---|---|---|
| Price | $1.55 | $0.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 216.6K | ★ 1.6M |
| Earning Date | 06-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $0.49 |
| 52 Week High | $2.82 | $3.70 |
| Indicator | FNUC | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 42.37 |
| Support Level | $1.54 | $0.58 |
| Resistance Level | $1.85 | $0.79 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 24.71 | 22.89 |
Frontier Nuclear and Minerals Inc is developing a U.S.-focused front-end nuclear fuel cycle company through a portfolio of U.S. uranium exploration and development projects in Wyoming, Colorado, and Utah, together with investments in next-generation uranium enrichment and small modular reactors. Frontier Nuclear is actively evaluating value-accretive investment opportunities in other sectors of the domestic U.S. nuclear fuel cycle. The group is developing a portfolio of critical minerals projects in America, Canada, and Namibia, including uranium, tantalum, cesium, and lithium. Its projects are Engo Valley, Pine Ridge, Shatford Lake, Snow Lake Lithium, and Tallahassee.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.